Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833181 | 0.93 | NR5A1 (0.40) | SMN1; SMN2NPC1RAB9AHSD17B10LTA4H | |
| SCHEMBL159611 | 0.91 | KMT2A (0.35) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL358869 | 0.84 | KDM4E (0.36) | SMN1; SMN2HSD17B10ALDH1A1L3MBTL1CYP1A2 | |
| SCHEMBL162984 | 0.82 | NQO1 (0.36) | SMN1; SMN2NPC1ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL359664 | 0.81 | LMNA (0.34) | SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL359290 | 0.81 | HTR2C (0.35) | ALDH1A1TDP1L3MBTL1KMT2AMEN1 | |
| SCHEMBL2677998 | 0.81 | LTA4H (0.46) | RAB9ALTA4HCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3525229 | 0.79 | LTA4H (0.36) | SMN1; SMN2NPC1RAB9AALDH1A1LTA4H | |
| SCHEMBL28224237 | 0.79 | LTA4H (0.44) | RAB9AL3MBTL1LTA4HCYP1A2CYP2C9 | |
| SCHEMBL5147091 | 0.78 | ALDH1A1 (0.44) | HSD17B10ALDH1A1TDP1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| CN-103384668-A | Novel compounds and compositions for inhibiting NAMPT | FORMA THERAPEUTICS INC | 2013-11-06 | — | — | CN | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | claimed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | claimed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | claimed |
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | claimed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | disclosed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | SMN1; SMN2 478/4885NPC1 282/4885RAB9A 1014/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | SMN1; SMN2 1497/4885NPC1 123/4885RAB9A 1445/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | SMN1; SMN2 1001/4885NPC1 174/4885RAB9A 1917/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | SMN1; SMN2 1497/4885NPC1 123/4885RAB9A 1445/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | SMN1; SMN2 1001/4885NPC1 174/4885RAB9A 1917/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | SMN1; SMN2 550/4885NPC1 651/4885RAB9A 1130/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | SMN1; SMN2 1001/4885NPC1 174/4885RAB9A 1917/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | SMN1; SMN2 1497/4885NPC1 123/4885RAB9A 1445/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | SMN1; SMN2 1497/4885NPC1 123/4885RAB9A 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.